Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:ABT
  • CUSIP: 00282410
  • Web:
  • Market Cap: $91.23313 billion
  • Outstanding Shares: 1,737,443,000
Average Prices:
  • 50 Day Moving Avg: $50.14
  • 200 Day Moving Avg: $47.04
  • 52 Week Range: $37.38 - $52.60
  • Trailing P/E Ratio: 73.54
  • Foreward P/E Ratio: 18.82
  • P/E Growth: 1.83
Sales & Book Value:
  • Annual Revenue: $23.61 billion
  • Price / Sales: 3.86
  • Book Value: $18.19 per share
  • Price / Book: 2.89
  • Annual Dividend: $1.06
  • Dividend Yield: 2.0%
  • EBIDTA: $5.14 billion
  • Net Margins: 4.96%
  • Return on Equity: 14.43%
  • Return on Assets: 6.47%
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 2.94%
  • Quick Ratio: 2.41%
  • Average Volume: 5.27 million shs.
  • Beta: 1.06
  • Short Ratio: 2.35

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, September 15th. Stockholders of record on Friday, October 13th will be paid a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.02%. The ex-dividend date of this dividend is Thursday, October 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its earnings results on Thursday, July, 20th. The company reported $0.62 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.60 by $0.02. The firm earned $6.64 billion during the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business's quarterly revenue was up 24.5% on a year-over-year basis. During the same period last year, the business earned $0.55 EPS. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, October, 18th 2017. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its third quarter earnings guidance on Thursday, July, 20th. The company provided EPS guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

12 brokerages have issued 1-year target prices for Abbott Laboratories' shares. Their forecasts range from $42.00 to $58.00. On average, they anticipate Abbott Laboratories' share price to reach $53.25 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary
  • Stephen R. Fussell, Executive Vice President - Human Resources
  • Brian J. Blaser, Executive Vice President - Diagnostics Products
  • John M. Capek Ph.D., Executive Vice President - Ventures
  • Robert B. Ford, Executive Vice President - Medical Devices
  • Heather L. Mason, Executive Vice President - Nutritional Products
  • Roger Bird, Senior Vice President - U.S. Nutrition

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.48%), BlackRock Inc. (6.01%), State Street Corp (4.43%), Capital Research Global Investors (2.74%), Bank of New York Mellon Corp (1.94%) and Northern Trust Corp (1.55%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Fort Washington Investment Advisors Inc. OH, FMR LLC, Macquarie Group Ltd., BlackRock Inc., Prudential PLC and DnB Asset Management AS. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Boston Partners, Principal Financial Group Inc., Parametric Portfolio Associates LLC and Hexavest Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $52.51.

MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  568 (Vote Outperform)
Underperform Votes:  419 (Vote Underperform)
Total Votes:  987
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $53.25 (1.41% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/24/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
9/1/2017BMO Capital MarketsReiterated RatingHold$53.00N/AView Rating Details
8/17/2017Citigroup Inc.Initiated CoverageNeutral -> Neutral$53.00MediumView Rating Details
8/3/2017Jefferies Group LLCReiterated RatingBuy$58.00LowView Rating Details
7/22/2017Barclays PLCReiterated RatingOverweight$52.00 -> $57.00LowView Rating Details
7/21/2017Stifel NicolausReiterated RatingBuy$58.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
6/30/2017Wells Fargo & CompanyReiterated RatingOutperform$47.50 -> $54.00LowView Rating Details
6/29/2017GuggenheimInitiated CoverageBuy$58.00LowView Rating Details
6/21/2017BTIG ResearchInitiated CoverageBuy$56.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$45.00LowView Rating Details
5/15/2017Royal Bank Of CanadaReiterated RatingBuyLowView Rating Details
9/19/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/18/2017$0.66N/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.63 billion$6.64 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20173$0.59$0.61$0.60
Q3 20173$0.64$0.68$0.66
Q4 20173$0.72$0.73$0.73
Q1 20182$0.55$0.56$0.56
Q2 20182$0.69$0.71$0.70
Q3 20182$0.74$0.76$0.75
Q4 20182$0.80$0.84$0.82
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Next Dividend:11/15/2017
Annual Dividend:$1.06
Dividend Yield:2.02%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:149.30% (Trailing 12 Months of Earnings)
42.57% (Based on This Year's Estimates)
37.99% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.50%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.00View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.44View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
DateHeadline logoAbbott Laboratories (ABT) Raised to Buy from a Hold - September 26 at 10:05 AM logoCowen and Company Reiterates Buy Rating for Abbott Laboratories (ABT) - September 24 at 6:30 AM logoBecton Dickinson - An Interesting Addition To Your Portfolio - Seeking Alpha - September 23 at 3:35 PM logoAbbott Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD - September 22 at 12:20 PM logoHere's Why You Should Add Abbott (ABT) to Your Portfolio Now - September 22 at 12:20 PM logoAbbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research - September 22 at 11:30 AM logoAbbott Hosts Conference Call for Third-Quarter Earnings - September 20 at 3:18 PM logoBuy Abbott Laboratories - Cramer's Lightning Round (9/15/17) - Seeking Alpha - September 18 at 8:35 PM logoIWB, SLB, ABT, UNP: Large Outflows Detected at ETF - September 18 at 3:33 PM logoAbbott Laboratories’ 375th Consecutive Quarterly Dividend - September 18 at 3:33 PM logoAbbott Laboratories (ABT) Expected to Post Quarterly Sales of $6.71 Billion - September 18 at 9:40 AM logoAbbott Laboratories (ABT) Receives Average Recommendation of "Buy" from Analysts - September 17 at 9:02 AM logoZacks: Brokerages Anticipate Abbott Laboratories (ABT) to Post $0.65 Earnings Per Share - September 16 at 6:12 AM logoAlibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round - - September 15 at 11:41 PM logoAbbott Laboratories (ABT) Announces Quarterly Dividend of $0.27 - September 15 at 5:52 PM logoHead-To-Head Contrast: Abbott Laboratories (ABT) versus Its Peers - September 14 at 8:28 PM logoAbbott Declares 375th Consecutive Quarterly Dividend - September 14 at 3:19 PM logoFreeStyle® Libre Flash Glucose Monitoring Technology Gains Reimbursement Approval from the United Kingdom's National Health Service - September 14 at 1:33 AM logo3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) - - September 12 at 3:23 PM logoCan Abbott Top Its All-Time High? - September 7 at 8:20 PM logoAbbott (ABT) Hits a 52-Week High: What's Driving the Stock? - September 7 at 3:19 PM logoAbbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index (DJSI) - September 7 at 3:19 PM logoETFs with exposure to Abbott Laboratories : September 7, 2017 - September 7 at 3:19 PM logoAbbott Laboratories :ABT-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 - September 5 at 3:29 PM logoAbbott Laboratories (ABT) Stock Rating Reaffirmed by BMO Capital Markets - September 2 at 10:38 AM logoAbbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod - Nasdaq - September 1 at 3:44 PM logoAbbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm - September 1 at 3:44 PM logoAbbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod - September 1 at 3:44 PM logoRevolutionary Glucose Monitoring Technology FreeStyle® Libre Now Reimbursed Across Japan - August 31 at 3:20 PM logoAbbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking - - August 30 at 8:24 PM logoAbbott software updates aim to fix pacemaker battery issues, hacking risks - August 30 at 3:22 PM logoAbbott Updates Pacemaker, Defibrillator Software to Protect Against Hacking - August 30 at 3:21 PM logoAbbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns - August 30 at 3:21 PM logoAbbott Laboratories (ABT) Expected to Announce Quarterly Sales of $6.71 Billion - August 30 at 5:34 AM logoAbbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - Nasdaq - August 29 at 8:46 PM logoAnalysts’ Recommendations for Pfizer in August 2017 - August 29 at 8:46 PM logoAbbott Releases New Software Updates for Pacemakers - August 29 at 8:46 PM logoTop Momentum Picks In Blue-Chip Health Care - August 29 at 3:45 PM logoTop Momentum Picks In Blue-Chip Health Care - August 29 at 3:45 PM logoAbbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - August 29 at 3:45 PM logoAbbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - August 29 at 3:45 PM logoAbbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - August 29 at 3:45 PM logoAbbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm - August 29 at 3:45 PM logoAbbott releases new round of cyber updates for St. Jude pacemakers - August 29 at 3:45 PM logoAbbott releases new round of cyber updates for St. Jude pacemakers - August 29 at 3:45 PM logoAbbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts - August 29 at 3:45 PM logoAbbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts - August 29 at 3:45 PM logoFDA Approves Abbott Heart Device, Stock Rises - - August 28 at 8:37 PM logoTechnical Snapshots for These Medical Equipment Stocks -- Abbott Labs, Boston ... - August 28 at 3:34 PM logoAbbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients - August 28 at 3:34 PM



Abbott Laboratories (ABT) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff